Phaseline

Companies › Atrium Therapeutics

Atrium Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATR 1072
siRNA targeting PRKAG2 to reduce gene expression
PRKAG2Phase 1Cardiac GlycogenosisMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07738107ATR 1072Phase 1Cardiac GlycogenosisCardiovascularMay 2028

From the company's SEC filings

Cash and short-term investments of $264m on 2026-06-30; operating cash outflow about $71m a year; runway about 44 months at that burn, to Mar 2030

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PRKAG2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.